• Call: 518-210-7164
  • Email: info@biomedinnova.net

Latest Post

Style

Default

BI Insight: Mixing, Diluting, or Repackaging Biological Products

Biologic agents are used in high volumes in oncology and auto immune diseases. The FDA acknowledges that at times, patients require different concentrations due to each patient’s genome. Outsourcing facilities are permitted to repackage biologic

BI Insight: Manufacturing Practice for Pharmaceuticals

Pharmaceutical drug products deliver over 446 billion dollars of revenue annually in the United States. The FDA is tasked with protecting the public by minimizing the risks to consumers and ensuring that all medications are

BI Insight: Mixing, Diluting, or Repackaging Biological Products

Biologic agents are used in high volumes in oncology and auto immune diseases. The FDA acknowledges that at times, patients require different concentrations due to each patient’s genome. Outsourcing facilities are permitted to repackage biologic

BI Insight: Manufacturing Practice for Pharmaceuticals

Pharmaceutical drug products deliver over 446 billion dollars of revenue annually in the United States. The FDA is tasked with protecting the public by minimizing the risks to consumers and ensuring that all medications are

Style

Image Bottom

BI Insight: Mixing, Diluting, or Repackaging Biological Products

Biologic agents are used in high volumes in oncology and auto immune diseases. The FDA acknowledges that at times, patients require different concentrations due to each patient’s genome. Outsourcing facilities are permitted to repackage biologic

BI Insight: Manufacturing Practice for Pharmaceuticals

Pharmaceutical drug products deliver over 446 billion dollars of revenue annually in the United States. The FDA is tasked with protecting the public by minimizing the risks to consumers and ensuring that all medications are

Style

No Image

BI Insight: Mixing, Diluting, or Repackaging Biological Products

Biologic agents are used in high volumes in oncology and auto immune diseases. The FDA acknowledges that at times, patients require different concentrations due to each patient’s genome. Outsourcing facilities are permitted to repackage biologic

BI Insight: Manufacturing Practice for Pharmaceuticals

Pharmaceutical drug products deliver over 446 billion dollars of revenue annually in the United States. The FDA is tasked with protecting the public by minimizing the risks to consumers and ensuring that all medications are